HC Wainwright & Co. Maintains Buy Rating for Verrica Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained its Buy rating for Verrica Pharmaceuticals (NASDAQ:VRCA) and increased its price target from $11.00 to $12.00. Despite this, Verrica's shares have fallen by 2.92% over the last 24 hours, trading at $5.15 per share. A move to $12.00 would represent a 133.01% increase from the current share price.
July 27, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verrica Pharmaceuticals' stock has been given a Buy rating by HC Wainwright & Co., with a raised price target of $12.00. However, the stock has recently fallen by 2.92%.
The maintained Buy rating and increased price target by HC Wainwright & Co. indicates a positive outlook for Verrica Pharmaceuticals. However, the recent drop in share price may cause some investor concern.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100